News Hub | News Direct

MGC Pharmaceuticals makes good progress with CimetrA and CannEpil treatments

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals chief commercial officer Robert Clements joined Proactive's Stephen Gunnion with details of the company's activity in the first quarter of 2023, as well as upcoming milestones. Clements noted that clinical trials of its CimetrA drug continue to demonstrate anti-inflammatory effects, with the results set to be used in a US new drug submission, adding that the US market holds significant potential for the company. This year, he said the company will also focus on expanding access to CannEpil in Europe, and advancing its cannabinoid-based investigational products. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 10, 2023 04:16 AM Eastern Daylight Time

Video

Monogram Orthopedics Plans NASDAQ Listing After Reg A+ Funding Round Concludes

Monogram Orthopedics

Monogram Orthopedics will conclude their Reg A+ funding round in preparation for their planned Nasdaq listing under the reserved ticker symbol “MGRM.” Monogram is working to develop patient-optimized, 3D-printed orthopedic implants enabled by robotics with advanced pre-operative imaging. Investors who wish to participate in the offering can subscribe at Monogram Orthopedics |Reg A+ Investment and hit the invest now button after reviewing the Company’s offering documents. The ability to subscribe to the offering on the Company’s site will conclude on May 10, 2023. Approximately 1.7 million patients receive knee replacement surgeries each year, but up to 20% experience chronic pain after the procedure. In addition, 40% of total knee replacement revision surgeries are caused by mechanical loosening, showing a need to improve knee implants for better fixation. Because of this, one-in-five patients report high levels of dissatisfaction after their procedure, with over a third of patients (36%) reporting they wouldn’t choose to have the procedure if they could do it again. Monogram Orthopedics plans to address these issues by 3D-printing FDA-approved implants tailored to each patient's unique anatomy. They are developing low-latency active-milling robots to make the precise cuts needed for custom implants, which aims to reduce the number of incisions and bone loss during surgery. “By 2027 50% of knee replacement surgeries will be performed robotically. Monogram is currently the only company offering FDA-approved, 3D printed, patient-specific implants that, in the future, will be inserted with active milling robots,” Benjamin Sexson, CEO of Monogram Orthopedics said. “With the coming close of our current Reg A+ funding round we are happily looking forward to our planned public listing. We imagine our investors will be just as excited as we are to one day see ‘MRGM’ scrolling on the ticker outside the NASDAQ exchange’s building in Times Square,” he added. “Having been a critical part of the Monogram development and heavily involved in building the formative technology as the Company's longest-tenured employee, I can say on behalf of myself and my colleagues that this planned listing will be a tremendous accomplishment. It has been an honor to help push this engineering effort and to have had the opportunity to play such a critical role in developing this transformative product.” Sanath Vurelli, Senior Robotics Engineer, at Monogram Orthopedics said. The company recently demonstrated a total knee replacement surgery by a surgeon operating in New York City on a cadaver patient in Austin, Texas. Their 3D-printed replacement’s patented design facilitates a bone-to-implant bond so they do not rely on bone cement. ABOUT MONOGRAM ORTHOPEDICS Monogram Orthopedics is working to develop a product solution architecture with the long-term goal to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The Company has a robot prototype that can autonomously execute optimized paths for high precision insertion of implants in synthetic bone specimens. Monogram intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. The Company has not yet made 510(k) premarket notification submissions or obtained 510(k) clearances for any of its robotic products. FDA approval is required to market these products, and the Company has not obtained FDA approval for any of its robotic products, and it cannot estimate the timing, or assure the ability, to obtain such clearances. Monogram Orthopedics changing the way orthopedic surgery is done. Our system combines personalized knee implants with precision robotic surgical assistants, giving patients a better-fitting knee replacement with minimally invasive surgery. 100,000 knee replacements failing each year in a $19.4B market, represents an enormous opportunity for us. This press release may include ''forward-looking statements.'' To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Monogram Orthopedics Inc.’s business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' Although Monogram Orthopedics Inc. believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Monogram Orthopedics Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Monogram are highly speculative. Investing in shares of Monogram involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. Monogram intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Monogram, the offering and any other related topics, please review the Form 1-A offering circular that can be found at the following location EDGAR Entity Landing Page (sec.gov). Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular: https://www.sec.gov/Archives/edgar/data/1769759/000110465923024829/tm237645d1_partiiandiii.htm DealMaker Securities, LLC is being compensated a 4% commission from the lead Selling Agent engaged by Monogram Orthopedics Inc. The Company has engaged Digital Offering, LLC (“Digital Offering”) to act as lead selling agent (which we sometimes refer to as the “Selling Agent”) to offer the shares of our common stock, par value $0.001 (the “Common Stock”) to prospective investors in this offering on a “best efforts” basis, which means that there is no guarantee that any minimum amount will be received by the Company in this offering. The Company will pay a cash commission of 7.00% to Digital Offering on sales of the shares of Common Stock. See “Plan of Distribution” in the Offering Circular for details of compensation payable to the Selling Agent in connection with the offering. DealMaker Securities, LLC is not affiliated with other companies mentioned herein. Contact Details Monogram Orthopedics Loreana Davi +1 512-790-5151 info@monogramorthopedics.com Company Website https://invest.monogramorthopedics.com/

May 09, 2023 10:58 AM Eastern Daylight Time

Emergent Health Subsidiary PharmaZu Retains BF Borgers to Audit its Financial Statement as required by the Engagement Letter with Boustead Securities

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced that it has engaged BF Borgers CPA PC, a full-service audit, tax, accounting, and advisory firm, as its Public Company Accounting Oversight Board (“PCAOB”) qualified auditor to audit the Company’s financial statement for the two-year period ending December 31 st, 2022 according to Generally Accepted Accounting Principles (“GAAP”). GAAP is the accounting standard adopted by the Securities and Exchange Commission (“SEC”) and is the default accounting standard used by companies based in the United States. Just last week on Thursday May 4 th, 2023, Emergent executed an Engagement Letter with Boustead Securities LLC. to act as exclusive financial advisor with respect to a planned corporate financing transaction including the private placement of securities (“pre-IPO Financing”) and a planned $10 million initial public offering of Emergent subsidiary PharmaZu common stock (“IPO”) that will apply for listing on NASDAQ with NO DILUTION to the Emergent Shareholders. PharmaZu is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including pet pharmacy, vet telehealth and pet wellness businesses. Upon the effectiveness of the IPO and listing on NASDAQ, PharmaZu plans to acquire a 48-state authorized compounding pharmacy located in West Palm Beach, FL, doing approximately $10M a year in revenue, which will serve as the backbone and fulfilment center for PharmaZu, creating a national platform throughout the United States. The raise of capital will be used for expanding PharmaZu’s business, product offerings, as well as for acquisitions. Subsequently, Emergent plans to distribute the shares of PharmaZu as a dividend to its shareholders, pro rata at NO COST to the Emergent Shareholders. Jim Morrison, former L'Oréal President and Emergents full time CEO stated, “As we first announced last week, the PharmaZu IPO is not only an enormous opportunity for the founders and leadership of PharmaZu, it is also a seminal event for the shareholders of Emergent Health. We are very serious about the PharmaZu IPO and have selected a "best-in-class" audit firm in B F Borgers as our 'PCAOB' audit firm. They are consummate professionals, and we are looking forward to working with the firm.” The execution of the Engagement Letter does not constitute a commitment by Boustead or the Company to consummate any transaction contemplated hereunder and does not ensure the successful placement of securities of any investment vehicle or the success of Boustead with respect to finding any investors or the success with respect to any transaction. No promises, representations or guarantees have been made. ABOUT BOUSTEAD SECURITIES, LLC Boustead Securities, LLC is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority-owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information visit please visit: www.boustead1828.com ABOUT BF BORGERS CPA PC BF Borgers CPA PC is based in Lakewood, Colorado and is registered as a Public Company Accounting Oversight Board (PCAOB) listed firm. At BF Borgers CPA PC we have built our practice by providing exceptional service to our clients through our commitment to our firm’s culture and values based on the three underlying principals Professionalism, Responsiveness and Quality. For More information, please visit BF Borgers CPA PC. ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website i nfo@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 09, 2023 09:15 AM Eastern Daylight Time

Thai Leaf aims for a breakthrough in Thailand’s healthcare industry with its high-quality CBD oil and CBD infused products.

Thai Leaf Biotechnology Co., Ltd.

BANGKOK, THAILAND - Media OutReach - 9 May 2023 - As Thailand is now the first country in ASEAN to liberalize hemp and cannabis for medical use, Thai Leaf Biotechnology Co., Ltd. has unveiled its plan to develop products with CBD extract, to address the needs of the medical and healthcare market in Thailand and ASEAN. Mr. Robert Traill and Mr.Christopher Utz from Thai Leaf Biotechnology Co., Ltd. From recent developments in the Thai market, it is understandable for consumers and the general public to have controversial issues and resistance to this important breakthrough, as they are still confused between hemp and marijuana - the two varieties within the Cannabis family. Christopher Utz, Director of Product Development at Thai Leaf explained that the clear difference is that hemp contains high levels of CBD but low levels of THC, making it safe, unlike marijuana, which has THC levels in excess of 0.2%, making it narcotic, or making one "high". Generally speaking, THC acts on the nervous system to give an intoxicating effect, while CBD has no side effects, but has numerous therapeutic and medical benefits, as well as bringing the body back to its "neutral strange". Simply put, hemp is known for health as opposed to marijuana which is used for recreational purposes. Not generally known, hemp is one of the most useful plants on Earth. Among thousand other uses, it can be used to make materials, ropes, textiles, and paper, it can be used as fuel and can also be consumed. More recently, it has been developed for nutraceutical and pharmaceutical use. Mr. Utz further emphasized the science behind the benefits of CBD discovered merely 30 years ago. The endocannabinoid system (ECS) is a biological regulating system comprised of molecules called endocannabinoids naturally produced by the human body, -i.e. to help maintain homeostasis or, in other words, "balancing" your body, easing pain, sleep, mood, energy, inflammation and appetite. Cannabinoids such as CBD are found naturally within the cannabis plant and can mimic the functions of endocannabinoids and help to address any imbalance within the body. Mr. Utz looks forward to the introduction of Thai Leaf's outstanding hemp-infused nutraceutical and pharmaceutical products in 2023. All Thai Leaf products have a tremendous amount of experience and research behind them and they will have a noticeable health impact for its consumers. Robert Traill, President of Thai Leaf announced that Thai Leaf has a 3-year research collaboration with world's leading Cornell University, in the United States to develop a new tropical hemp strain for Thailand. The new strain would be able to grow with shorter day-lengths, be resistant to mold and have high CBD potency with negligible THC. With the founders' extensive background and experience in both the agricultural and pharmaceutical industry, Thai Leaf's end-game is in pharmaceutical CBD products. This background is what distinguishes Thai leaf from other producers. It has the experience of the highest production standards and combines it with expertise and know-how from the US and Canada. Mr. Traill is extremely positive about the growth of the industry in Thailand. The Thai CBD market is currently worth THB 7 billion, and forecasted to grow to THB 50 billion within the next three years. Thailand is the first country in the region to legalize hemp-derived CBD, and is in a unique and strong position to be a leader in the ASEAN region of 650 million potential consumers. Currently, due to the ambiguous stage of the laws, there may be unstandardized products that do not possess the claimed qualities and may contain undesirable compounds. Thai Leaf calls for a benchmark of standardization and traceability, which all producers need to adhere to, so that the consumer is guaranteed with the highest quality of products. The extraction and distillation of hemp biomass to produce high quality cannabinoids and CBD is an important step in providing fine quality products for the CBD industry. "There are simply no shortcuts to having good equipment and systems in place". Thai Leaf's final focus is pharmaceutical (medical) CBD. Therefore, it is essential that its factory is built to US GMP and European PIC/s standard (the highest standard for the medical industry) utilizing world-leading extraction, distillation and crystallization equipment from the US and Germany. Having Master Growers from the US and importing standard operation systems, also allows Thai Leaf to leverage decades of experience and know-how within its products. To summarize, with the right regulations in place, standards will automatically rise for all manufacturers, making it possible for Thailand to become a hub and regional leader for Hemp-derived raw materials, nutraceutical and pharmaceutical products, with high hopes that hemp becomes an economic crop for the Kingdom of Thailand. Find out more at the website https://thaileaf.com/. Media outlets requiring more information can make contact by e-mail on info@thaileaf.com Thai Leaf Biotechnology Co., Ltd. Thai Leaf is the first generation company to be licensed in Thailand for hemp derived CBD. We are vertically integrated from seed to pharmaceutical. The most valuable asset is our talented team of US experts who bring to Thailand their know-how and experience in the areas of seeds and strains, cultivation, and production. Contact Details JC&CO COMMUNICATIONS Watcharakorn Touthong watcharakornt@jcco.co.th JC&CO COMMUNICATIONS Kanyawee Wimolrat kanyaweew@jcco.co.th Company Website https://thaileaf.com/

May 09, 2023 09:00 AM Eastern Daylight Time

Image

News Release

Relief Therapeutics prepares for Nasdaq listing following transition into commercial-stage company

Relief Therapeutics

Relief Therapeutics CEO Jack Weinstein tells Proactive's Stephen Gunnion that a reverse 1-for-400 stock split has taken effect at the company as it targets a listing on the Nasdaq in a move that will raise its profile and attract more institutional investors. Weinstein also takes Proactive through the company's commercial and development drug pipeline as it makes progress with its transformation into a commercial-stage biopharmaceuticals company, identifying, developing and commercializing novel, patent-protected products in selected specialty, rare and ultra-rare disease areas on a global basis. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

May 09, 2023 07:36 AM Eastern Daylight Time

Video

Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation

Kadimastem Ltd.

Kadimastem (TASE: KDST) announced today that it has signed a collaboration agreement with US based company iTolerance Inc. Kadimastem and iTolerance with the signing of the agreement received their 1 st milestone payment of the NIS 3.65 million (US$1 million) total grant by Israel-U.S. Binational Industrial R&D Foundation (BIRD) for their joint project to co-develop and commercialize a breakthrough and innovative regenerative technology to cure diabetes without the need for chronic immunosuppression. As part of the agreement Kadimastem will supply its advanced cell product for the treatment of diabetes called IsletRx, which is comprised of clinical-grade clusters of human pancreatic islet like cells (ILCs) with the ability to secrete insulin. IsletRx cells can detect the sugar levels in the body and produce the required amounts of insulin and glucagon, just like a healthy pancreas can, and enables the insulin dependent patient to avoid an abnormal drop in sugar level (hypoglycemia). iTolerance will provide its technology (iTOL-100) intended to enable the transplantation of allogeneic cells without tissue matching and without the need for chronic treatments that suppress the immune system of the transplant recipient (immunosuppression). This platform technology has demonstrated positive results in preclinical experiments in large animals (non-human primates), where implanted pancreatic cells were shown to act as native cells, secreting insulin in response to sugar intake, without the need for long-term immunosuppressive treatments. The funding will be used to support the joint project that combines the technologies towards clinical application of iTOL-102, an allogeneic cell product intended to utilize stem cell derived pancreatic islets which allows an inexhaustible supply of insulin-producing cells that can be transplanted without the need for chronic immunosuppressive treatments. The prestigious grant was awarded by the BIRD Foundation after examining many projects. Earning the funding is a vote of confidence in the combined scientific potential and innovation presented in the joint project of Kadimastem and iTolerance for the treatment of diabetes. The project's total budget is US$2 million (~NIS 7.35 million ), of which the grant is US$1 million (~NIS 3.65 million), and will be allocated over a period of 30 months. The BIRD Foundation's decision was made after comprehensive due diligence and a competitive evaluation process between projects from different technology fields. Top experts in the field from both the Israel Innovation Authority and from the NIST in the US examined the combined project thoroughly, including the technology underlying the development, the regulatory pathway, and the ability and feasibility to commercialize and market the product that will be developed. The BIRD Foundation, established in 1977, invests in collaborations between Israeli and American companies in various fields of technology, for the development of joint products. In addition to financial support for grants, the fund assists companies in locating potential strategic partners and creating connections between the American and Israeli industry. Kadimastem CEO Asaf Shiloni said, “We are eager to begin our collaboration with iTolerance, which has developed a unique technology for cell transplantation without the need to suppress the immune system. The combination of Kadimastem’s abilities in the field of diabetes with iTolerance’s may in the future enable diabetic patients to live without the need for insulin injections, subject of course to regulatory compliances, and I believe that we will soon be able to bring a joint product to the clinic, with the aim to improve the lives of millions of diabetics worldwide”. Dr. Anthony Japour, Chief Executive Officer of iTolerance, added “We are excited to enter this agreement with Kadimastem to evaluate the combination of their stem cell technology with our proprietary iTOL-100 technology. We believe that this collaboration has the potential to provide a much-needed, innovative cure for the patients we work to serve and drive significant value for both companies. Additionally, we are grateful to the BIRD Foundation and their continued support and funding of the work as part of this agreement.” About Kadimastem Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). About iTolerance, Inc. iTolerance is an early-stage privately held regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging its proprietary biotechnology-derived Strepavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic pancreatic islets and stem cells that have the potential to cure diseases. The company’s lead program, iTOL-102, leverages significant advancements in stem cells to derive pancreatic islets which allows an inexhaustible supply of insulin-producing cells. Utilizing iTOL-100 to induce local immune tolerance, iTOL-102 has the potential to be a cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the company is developing iTOL-201 for the treatment of liver failure by utilizing hepatocytes and iTOL-401 as a nanoparticle formulation for large organ transplants without the need for life-long immunosuppression. For more information, please visit itolerance.com. At Kadimastem we envision being a global leader in cell therapy.Our passion and commitment keep us moving forward, to develop innovative regenerative therapies for incurable diseases. Our goal is to treat millions of patients around the world with that technology. Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under Kadimastem’s control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the company's activity, as well as developments in the general environment and external factors affecting the company's activity. The company's results and achievements in the future may differ materially from any presented herein and the company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the company's securities or an invitation to receive such offers. Investment in securities in general and in the company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Ltd. Asaf Shiloni +972 73-797-1613 INFO@kadimastem.com iTolerance Inc. Susan Roberts +1 202-779-0929 sr@roberts-communications.com Company Website https://www.kadimastem.com/

May 09, 2023 07:00 AM Eastern Daylight Time

CareTalk Health Launches First Chronic Care Telehealth Platform Specifically for Seniors

CareTalk Health

CareTalk Health, the first direct-to-consumer chronic care management (CCM) company, has launched its global telehealth platform that is designed specifically for seniors on Medicare/Medicaid with chronic medical conditions. The platform provides personalized, comprehensive virtual care and focuses on reducing emergency room visits and bridging the gap in care between doctor appointments. CareTalk provides seniors with the quality of care they need and deserve from the comfort of their own homes. The company is also committed to reaching seniors living in medical deserts, where access to quality healthcare is limited or non-existent. Through the CareTalk platform, medical staff are able to connect with and provide care for seniors living in remote areas and underserved communities. This is a critical step toward addressing healthcare disparities and ensuring that all seniors, regardless of their location, receive the care they need and deserve. “Millions of seniors need regular attention for their chronic conditions, yet so few of them have access to the providers who can consistently care for them in the way they require,” said Donnie Gross, CEO and founder of CareTalk Health. “Our platform provides a bridge between doctor’s appointments for seniors and offers a way to help them effectively manage their conditions from the comfort of their home by bringing them care coordination and extra attention. This attention, in turn, improves health outcomes, reduces costs, and supports Medicare’s and the U.S. healthcare system’s goal to reduce urgent care visits and hospitalizations.” According to the National Council on Aging, there are about 56 million people 65 and older. Of that number, 80% of them have two or more chronic conditions. As of March 2022, 86.2% of American seniors are on Medicare. CareTalk Health provides a virtual network of licensed medical professionals, who deliver top-tier, concierge CCM services. The goal is to improve the quality of life for seniors and guide them through the complexities of chronic conditions. Benefits for CareTalk Health patients include: 24/7 access to healthcare professionals A dedicated healthcare team familiar with a patient’s personalized plan, All services coverage by Medicare/Medicaid State-of-the-art technology proprietary technology stack HIPAA compliant organization A trusted organization of healthcare professionals For more information, please visit caretalkhealth.com. CareTalk Health is a national telemedicine platform dedicated to providing chronic care management (CCM) services to people 65 and older. The goal is to provide consumers with a supplemental resource for care between doctor’s visits from the comfort of their home. A dedicated team of medical expertise use the latest technology to provide 24/7 service. For more information, visit caretalkhealth.com. Contact Details Kite Hill PR Dorianne Kaboya caretalk@kitehillpr.com

May 08, 2023 09:00 AM Eastern Daylight Time

News Release

Mounjaro Weight Loss: Newly Launch Over The Counter Alternative Pills To Tirzepatide & Mounjaro Weight Loss

Allied PR

Adults suffering from type 2 diabetes can improve their blood sugar (glucose) levels by using the injectable prescription drug Mounjaro in conjunction with a healthy diet and regular exercise. Can Mounjaro assist with weight loss? Yes, it has been proven that taking Mounjaro, also known as tirzepatide, will help people with type 2 diabetes lose weight when used along with a healthy diet and regular exercise. It is injected under the skin of the stomach, thigh, or upper arm once a week, at any time of day. You should take it exactly as your doctor has advised. Mounjaro may be replaced with other over-the-counter supplements. Here are some of them: PhenQ - Top Choice for Mounjaro Alternative OTC PhenGold - Strongest OTC Mounjaro Weight Loss Alternative Capsiplex BURN - Best Choice for Men to Mounjaro Alternative Trimtone - Best Choice for Women to Mounjaro Alternative Primeshed - Best Fat Burner for Men to Tirzepatide Alternative These are the pills for weight loss that work the best. No solution works for everyone. That is why there are several options on this list. All of them will aid in fat loss, but all have different additional advantages. Finding the optimal weight-loss supplement is not the goal. You need to decide which weight-loss product is best for you. Presented herein are the most efficacious weight loss supplements available for purchase without a prescription, including those available through online markets. 1- PhenQ - Top Choice for Mounjaro Alternative OTC PhenQ is a comprehensive weight loss solution that effectively targets various regions of the body and has been widely regarded as a prominent inclusion in the most reputable listings of top-notch diet pills. Not only does it facilitate prompt fat loss, but it also expedites the entire weight-reduction journey. (ACT NOW & SAVE) Click Here to GET PhenQ From The Official Website The manufacturer provides a warranty period of two months for its clientele. If an individual is striving to reduce their weight and is currently experiencing a plateau or experiencing factors such as fatigue and increased appetite which are hindering their progress, PhenQ may provide effective assistance. Advantages of Using PhenQ for Dietary Management If your objective is to acquire an efficacious weight reduction supplement, PhenQ is highly recommended. PhenQ has demonstrated compatibility with most weight loss medications, including those available by prescription. Pros Facilitates weight loss in multiple pivotal regions. Vegan and vegetarian friendly There are no officially acknowledged negative consequences. Excellent customer feedback Our company provides a refund policy that extends for a period of 60 days. Cons Exclusively obtainable via the designated website 2. PhenGold - Strongest OTC Mounjaro Weight Loss Alternative Almost everyone who tried PhenGold loved it - it has a 98% satisfaction score! Lots of people said they would totally recommend this product. PhenGold is one of the top weight loss supplements that speed up your metabolism. It makes you less hungry, fights fatigue, and might even make you feel better. Click Here to Get PhenGold From Its Official website The cool thing about it is that you get a whopping 100 days to try it out and get your cash back if you are not happy. Benefits Manages Hunger and Cravings Makes your body burn fat faster and revs up your metabolism. Helps you focus better and think more clearly. Gives you a boost of energy and helps you feel better emotionally. Pros Losing weight isn't the only upside, there's a lot more to it. Vegan and vegetarian friendly So far, nothing bad seems to be happening. Excellent customer feedback You can get your money back if you're not happy with it within 100 days! Cons You can only get to it by going through the official website. 3. Capsiplex BURN - Best Choice for Men To Mounjaro Alternative This supplement is supposed to help you burn fat faster and keep your blood sugar levels in check. So basically, this supplement does six things at once. It helps you keep your muscles, kills your hunger, gives you more energy, and torches stubborn fats for a fit and cut appearance. Click Here to Buy Capsiplex BURN From The Official Website Yes, this supplement does six different things! It helps to torch that extra flab! It stems cravings It stops fatigue It increases metabolism It helps keep your muscles in shape. It gets you pumped for a workout. Benefits This is a vegan product that doesn't have any gluten in it! The manufacturer makes it in GMP certified facilities. It's made in the US. It helps you get you back to the grind after a rough patch. It gives your metabolism a little boost! It totally helps you bust through that plateau! You can gain some muscle without getting all flabby and stuff! It's important to keep those gains and not lose muscle when you are shredding in the gym. 4. Trimtone - Best Choice for Women To Mounjaro Alternative Trimtone kicks butt when it comes to weight loss pills for women and even beats out a bunch of those male-oriented ones. If you go with this option, it won't mess with your estrogen levels and it's pretty good at curbing your cravings. Click Here to Order Trimtone for the Best Price Available! Trimtone's got some legit ingredients you can trust. And you know what's even better? You only have to take it once a day! Trimtone is perfect for busy women who juggle a million things and rock motherhood like a boss. Just a heads up - if you're vegan or vegetarian, those capsules won't work for you because they have got gelatin in them. Benefits Here are the benefits of Trimtone: It helps you lose weight and drops those extra pounds. Helps you eat less and avoid those pesky snack urges Increases metabolism Helps burn some extra calories by revving up the body's heat production! Boosts energy and vigor If you're always on the go and can only remember to take one pill a day, Trimtone could be your saving grace! Also, this is a diet pill that specifically attacks belly fat - same deal. If all you want to do is shed some fat, Trimtone could totally help you out. If you're always getting hungry, we suggest trying something else instead. Upsides and Downsides of Trimtone A fat-burning pill made for women that boosts metabolism and burns calories A pill that actually helps you lose weight Stuff that will help you burn fat and not feel as hungry. You only need to take it once a day. This product has something in it that helps burn belly fat! As far as we know, it's all good. You've got a complete 100 days to decide if you want your money back with no hassle. Cons Inadequate hunger control Those who don't eat meat might want to skip it. You can only get it on the website, no other way. 5. Prime Shred – Best Fat Burner for Men to Tirzepatide Alternative Prime Shred is a fat burner that boosts metabolism specifically for males. But don't expect it to do all the work when it comes to shedding those extra pounds. Men who are really serious about getting ripped might want to check this product out. Find Out More On Prime Shred By Visiting The Official Website It's supposed to be a real badass fat burner that can get you shredded without losing your hard-earned gains. Prime Shred also gives you an energy boost and helps you push harder during your workout. We added Prime Shred to our list for a reason, so don't forget about that. This is like the boss of all the natural weight loss pills out there! Benefits Promotes fat burning Helps burn fat but keeps those muscles intact Gives you a boost of energy and helps you focus during workouts. Helps you smash through those pesky plateaus! Why should you use Prime Shred? Prime Shred will take your workouts to the next level, torch those fats, and let you flex your muscles with pride! If you are like most of us and only work out a few times a week, Prime Shred might be a good option for you since you only need one dose a day. Let's talk about the good and bad of Prime Shred Pros There is just one dosage required each day. Provides tried-and-true metabolism boosters This stuff really gets me pumped before a workout. Gives you something that can help you avoid burnout. You have got a whole 100 days to decide if it's a match. And if you are a vegan or vegetarian, we've got you covered with a money-back guarantee. Cons You can only get it from their website. What is Mounjaro and how does it help with weight loss? Does it really work? Tirzepatide is available under the brand name Mounjaro. It's like a two-in-one drug that helps control sugar levels by activating two different receptors, the GIP and GLP-1 receptors. Basically, if you want to lose weight with diabetes meds, you are only gonna find GLP-1 receptor agonists. Tirzepatide is one of a kind since it also affects GIP. But the real deal with Mounjaro is that it's great for shedding some extra pounds as it works as a GLP-1 receptor agonist. Apparently, these drugs make you feel full for longer by slowing down your digestion, according to research. Click to view pricing on cheaper alternatives to Mounjaro in stock Losing Weight with Mounjaro: A Beginner's Guide Mounjaro is available in the form of pre-filled single-use Tirzepatide injector pens, dude. After you use a pen once, you just toss it in the bin. These Mounjaro injector pens come in six different strengths! First-timers usually start with the teeny-tiny pen (2.5 mg) and then upgrade every month until they hit the big dose (15 mg). Whether you're using Mounjaro to handle your type-2 diabetes or for weight loss, all you need is one shot a week and you're good to go! It is injected right under the skin, not in a muscle or vein or anything crazy like that. Most folks who use Mounjaro prefer sticking it in their belly 'cause it's easier, but you can also do it in your arms or thighs if you're up for it. Mounjaro helps to keep your blood sugar levels in check and fight against insulin resistance. They made it to help deal with diabetes and blood sugar levels. Who can benefit from Mounjaro? Mounjaro is a new diabetes medication that does an awesome job of keeping blood sugar levels in check! Mounjaro manufacturers understand the struggles of obesity in adults, so they've designed something truly special just for you. If you're carrying some extra weight around and have some health issues because of it, this medicine could be really helpful for you! Even if your BMI isn't off the charts, it could still do a lot of good. If you've got diabetes, high blood pressure, high cholesterol, or sleep apnea, then using Mounjaro could be a good way to stay on top of your medical game. Mounjaro is great for folks in these specific situations because it helps them get their blood sugar levels under control and boosts their general health and quality of life. Side Effects of Mounjaro Mounjaro tends to mess with your tummy the most. Here are some of the side effects of Mounjaro that you can experience. Indigestion Nausea Vomiting Stomach pain Constipation Diarrhea Some people using Moujaro also experience some annoying skin irritation around the place they injected it. Well, some folks might have side effects like these, but some wouldn't. It's different for everyone. All prescribed medicines work in the same way. Unfortunately, those GLP-1 receptor agonists come with some serious health issues to worry about. The Mounjaro website is pretty upfront about it - they've put all the information out there. So, there has been a lot of debate about whether GLP-1 receptor agonists can lead to thyroid cancer for a while now, but a new study published in Diabetes Care this year has some pretty concerning findings. So, after digging deep into this study, it turns out that using GLP-1 RA for 1-3 years can up your risk for thyroid cancer, including medullary thyroid cancer. Read: Best Weight Loss Supplements In Canada Is Mounjaro worth it for shedding some extra pounds? Thyroid cancer is one of the rare side effect but the worst side effect ever. There are some other possible side effects of Mounjaro also. But since not everyone will experience the same side effects, you can try out Mounjaro. A safer option would be to use one of the OTC supplements discussed above. Pros This could totally help you curb your hunger pangs and shed some pounds. You only have to take it once a week and you are done. Cons This may not be your cup of tea if you're not a fan of needles. That's a pricey way to shed those pounds. Mounjaro Weight Loss Alternative - Conclusion Mounjaro represents one of the most recent medicinal treatments aimed at managing the symptoms of type 2 diabetes. It is a pharmaceutical product that has been commercialized under a specific trademark, namely Tirzepatide. Similar to Ozempic and Wegovy, Mounjaro is administered via a weekly self-injection, as prescribed. Nevertheless, it is worth noting that while Ozempic is dispensed through a multi-shot pen, Mounjaro does not share the same mode of administration. It is provided in individual-dose pens. Although Mounjaro is not indicated for weight management, diabetic patients administered with it frequently report significant reduction in body weight. Empirical evidence is suggestive of the efficacy of Mounjaro in promoting weight reduction, albeit within confined parameters. It is not unexpected to note that certain physicians are inclined to endorse the administration of Mounjaro, albeit off-label, as a viable therapeutic measure for combating obesity. Similar to numerous pharmacological interventions for weight loss and diabetes, Mounjaro showcases a plethora of established adverse effects. Additionally, it can potentially evoke significant health hazards, such as pancreatitis and thyroid cancer. It is a potential downside that some overweight individuals may not be inclined to acknowledge. Armed with this knowledge, you would be better off using a natural OTC supplement that can give you the same benefits as Mounjaro but minus the side effects. Contact Details Melissa support@jollofnews.com

May 06, 2023 03:26 AM Eastern Daylight Time

Berkshire Hathaway Shareholder to Criticize Warren Buffett and Bill Gates for Politicized Philanthropy

National Legal & Policy Center

National Legal and Policy Center (NLPC) is the sponsor of a Berkshire Hathaway shareholder proposal to separate the roles of Chairman and CEO. On April 21, we filed a proxy memo in support of our resolution, explaining why we believe the succession plan is inadequate and that the company should be less identified with Warren Buffett’s politics. Here is the statement NLPC Chairman Peter Flaherty plans to make at the Berkshire annual meeting on Saturday, April 6 in Omaha, Nebraska: I am Peter Flaherty, Chairman of the National Legal and Policy Center. If we had an independent chair, the Company would be less identified with Mr. Buffett’s political activities. He’s donated more than $100 billion to the Bill and Melinda Gates Foundation. As Bill Gates explained when the couple was still together, “ although the foundation bears our names, basically half our resources have come from Warren Buffett.” If “woke” culture is a disease, then philanthropy is the virus. The Gates Foundation bankrolls the teaching of Critical Race Theory around the country, including that math is inherently racist. The Gates Foundation offers a Gender Identity Toolbox, which asserts that gender is the result of “socially and culturally constructed ideas.” This is a lie. Gender is not a cultural construct. It is a genetic and biological fact. We know how much Bill Gates cares about children. He met and traveled with Jeffrey Epstein MANY times AFTER Epstein was convicted of sex crimes. The Gates Foundation had a huge influence over the COVID response fiasco. Bill Gates defended China’s COVID policies and still discounts the possibility that the virus originated from a lab, even though U.S. intelligence agencies disagree. The Gates Foundation may be the largest single donor to the “dark money” machine known as Arabella Associates which funds causes like defunding the police that are making American cities unlivable. Money goes, too, to groups conducting threatening and vulgar protests at their homes of Supreme Court Justices. Mr. Buffett has quietly funneled more than $4 billion to groups supporting abortion on demand through the Susan Thompson Buffett Foundation. That’s $4 billion, with a B. Advocacy disguised as philanthropy. Bill Gates has lamented political polarization and even worried aloud about a civil war. But it is billionaires who are funding the most shrill and extreme activists who are tearing our country apart. Ironically, Mr. Buffett has pointed out that corporate executives can make a lot of people mad when they insert themselves into controversy. Anheuser-Busch is finding that out. It cannot renounce its Dylan Mulvaney transgender promotion because it is handcuffed by its longtime support for activists who would turn on them in a minute. Anheuser-Busch gets a perfect grade on the Human Rights Campaign scorecard, as do Berkshire portfolio companies like Coca-Cola, Bank of America, and Apple. Bank of America and Apple help bankroll this group, which wants biological men to compete in women’s sports. Worse, it is currently pressuring state legislatures to allow sex change operations on children, and to keep their parents out of the decision. Let’s revisit Coca-Cola, which I discussed at last year’s meeting. CEO James Quincey, a British citizen, tried to kill Georgia’s voter integrity law in 2021 by making inaccurate and inflammatory statements about it. That’s the law that President Biden called “Jim Crow 2.0,” and which prompted Major League Baseball to move the All-Star game out of Atlanta. Mr. Buffett jumped on the bandwagon, too, by signing a statement by corporate leaders suggesting that Republicans seek to restrict ballot access based on race. Two years later, we can now evaluate that accusation. Last year, an election was held in Georgia. Turnout was record breaking. According to an independent poll, 99% of voters said they had “no problem” casting ballots. 92% said the new law either had no impact on their ability to vote or made it easier. James Quincey was wrong, and Mr. Buffett, so were you. ### To schedule an interview with Peter Flaherty, please contact Dan Rene at drene@nlpc.org or Jackie Jones at jackie@truthpr.com Founded in 1991, NLPC promotes ethics in public life and government accountability through research, investigation, education, and legal action. Contact Details National Legal and Policy Center Dan Rene +1 202-329-8357 drene@nlpc.org Company Website http://www.nlpc.org

May 05, 2023 01:00 PM Eastern Daylight Time

Healthcare